CoChat

Vulnerabilities of PTEN – TP53 -Deficient Prostate Cancers to Compound PARP–PI3K Inhibition

Open access
González-Billalabeitia, Enrique, Seitzer, Nina, Song, Su Jung, Song, Min Sup, Patnaik, Akash, Liu, Xue-Song, Epping, Mirjam T., Papa, Antonella, Hobbs, Robin M., Chen, Ming, Lunardi, Andrea, Ng, Christopher, Webster, Kaitlyn A., Signoretti, Sabina, Loda, Massimo, Asara, John M., Nardella, Caterina, Clohessy, John G., Cantley, Lewis C., Pandolfi, Pier Paolo · 2014 · Cancer Discovery
Cited by 92

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Prostate cancer is the most prevalent cancer in males, and treatment options are limited for advanced forms of the disease. Loss of the PTEN and TP53 tumor suppressor genes is commonly observed in prostate cancer, whereas their compound loss is often observed in advanced prostate cancer. Here, we show that PARP inhibition triggers a p53-dependent cellular senescence in a PTEN-deficient setting in the prostate. Surprisingly, we also find that PARP-induced cellular senescence is morphed into an apoptotic response upon compound loss of PTEN and p53. We further show that superactivation of the prosurvival PI3K–AKT signaling pathway limits the efficacy of a PARP single-agent treatment, and that PARP and PI3K inhibitors effectively synergize to suppress tumorigenesis in human prostate cancer cell lines and in a Pten/Trp53–deficient mouse model of advanced prostate cancer. Our findings, therefore, identify a combinatorial treatment with PARP and PI3K inhibitors as an effective option for PTEN-deficient prostate cancer. Significance: The paucity of therapeutic options in advanced prostate cancer displays an urgent need for the preclinical assessment of novel therapeutic strategies. We identified differential therapeutic vulnerabilities that emerge upon the loss of both PTEN and p53, and observed that combined inhibition of PARP and PI3K provides increased efficacy in hormone-insensitive advanced prostate cancer. Cancer Discov; 4(8); 896–904. ©2014 AACR. This article is highlighted in the In This Issue feature, p. 855

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-13-0230

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 92

Metadata

Authors
González-Billalabeitia, E., Seitzer, N., Song, S. J., Song, M. S., Patnaik, A., Liu, X.-S., Epping, M. T., Papa, A., Hobbs, R. M., Chen, M., Lunardi, A., Ng, C., Webster, K. A., Signoretti, S., Loda, M., Asara, J. M., Nardella, C., Clohessy, J. G., Cantley, L. C., & Pandolfi, P. P.
Venue
Cancer Discovery
Published
2014-08-01
Volume
4
Issue
8
Pages
896-904
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W2169228223
Cited by
92
References
6
FWCI
5.17
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Vulnerabilities of PTEN – TP53 -Deficient Prostate Cancers to Compound PARP–PI3K Inhibition. https://app.cochat.ai/papers/10.1158/2159-8290.cd-13-0230
The paper
González-Billalabeitia, E., Seitzer, N., Song, S. J., Song, M. S., Patnaik, A., Liu, X.-S., Epping, M. T., Papa, A., Hobbs, R. M., Chen, M., Lunardi, A., Ng, C., Webster, K. A., Signoretti, S., Loda, M., Asara, J. M., Nardella, C., Clohessy, J. G., Cantley, L. C., & Pandolfi, P. P. (2014). Vulnerabilities of PTEN – TP53 -Deficient Prostate Cancers to Compound PARP–PI3K Inhibition. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-13-0230

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.